The role of deferred cytoreductive nephrectomy in the era of immune checkpoint inhibitor

被引：0
|
作者：
Yaegashi, Hiroshi [1 ]
机构：
[1] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY13-3
引用
收藏
页码：S1362 / S1362
页数：1
相关论文
共 50 条
  • [41] Cytoreductive nephrectomy in the era of targeted therapies: a review
    Pindoria, Nisha
    Raison, Nicholas
    Blecher, Gideon
    Catterwell, Rick
    Dasgupta, Prokar
    BJU INTERNATIONAL, 2017, 120 (03) : 320 - 328
  • [42] Assessing the survival advantage of deferred cytoreductive nephrectomy using a prediction interval
    Hung, Kuo-Chuan
    Tsai, I-Ting
    Sun, Cheuk-Kwan
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (03) : 1832 - 1833
  • [43] Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma
    Shen, X. -P.
    Xie, M.
    Wang, J. -S.
    Guo, X.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5684 - 5691
  • [44] Survival of Mucosal Melanoma Patients in the Immune Checkpoint Inhibitor Era
    Hsu, Charles
    Xing, Jessica
    Stea, Baldassarre
    Dougherty, Shona
    Shaheen, Montaser
    Christopher, Le
    Robbins, Jared
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S90 - S91
  • [45] GEOGRAPHICAL DIFFERENCES IN THE MANAGEMENT OF METASTATIC DE NOVO RENAL CELL CARCINOMA IN THE ERA OF IMMUNE COMBINATIONS WITH A FOCUS ON THE ROLE OF CYTOREDUCTIVE NEPHRECTOMY
    Mollica, Veronica
    Massari, Francesco
    Rizzo, Mimma
    Morelli, Franco
    Grande, Enrique
    Iacovelli, Roberto
    Molina-Cerrillo, Javier
    De Giorgi, Ugo
    Fornarini, Giuseppe
    Procopio, Giuseppe
    Buchler, Tomas
    Cattrini, Carlo
    Caffo, Orazio
    Ortega, Cinzia
    Soares, Andrey
    Messina, Carlo
    Monteiro, Fernando Sabino M.
    Rizzo, Alessandro
    Buti, Sebastiano
    Porta, Camillo
    Santoni, Matteo
    ANTICANCER RESEARCH, 2023, 43 (10) : 4769 - 4770
  • [46] Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
    Hahn, Andrew W.
    Kotecha, Ritesh R.
    Viscuse, Paul V.
    Pieretti, Alberto C.
    Wiele, Andrew J.
    Jonasch, Eric
    Lee, Chung-Han
    Gao, Jianjun
    Zurita, Amado J.
    Shah, Amishi Y.
    Campbell, Matthew T.
    Sharma, Padmanee
    Motzer, Robert J.
    Russo, Paul
    Wood, Christopher G.
    Tannir, Nizar M.
    Voss, Martin H.
    Karam, Jose A.
    Hakimi, A. Ari
    Msaouel, Pavlos
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 734 - 741
  • [47] Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis
    Garcia-Perdomo, Herney A.
    Zapata-Copete, James A.
    Castillo-Cobaleda, Diego F.
    INVESTIGATIVE AND CLINICAL UROLOGY, 2018, 59 (01) : 2 - 9
  • [48] Initial compared to deferred cytoreductive nephrectomy for metastatic kidney cancer and its association with improved survival in the targeted therapy era.
    Macleod, Liam Connor
    Tykodi, Scott S.
    Holt, Sarah
    Gore, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [49] Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Yoshino, Maki
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Nishimura, Koichi
    Tachibana, Hidekazu
    Fukuda, Hironori
    Toki, Daisuke
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1208 - 1214
  • [50] Cytoreductive nephrectomy improves outcomes in the era of targeted therapy
    Peter Sidaway
    Nature Reviews Urology, 2016, 13 (8) : 438 - 438
12345